A Phase 4 interventional study of Early receiving G-CSF group and Late receiving G-CSF group in Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor and Febrile Neutropenia (FN), sponsored by Department of Medical Services Ministry of Public Health of Thailand. Not yet recruiting at 3 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.
Sponsored by Department of Medical Services Ministry of Public Health of Thailand · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand — 2 open to participants now, 5 under way, 2 of them phase 3. Lymphoma, Non-Hodgkin · Thailand.
Among the 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand, this one is the 11th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 4, and was the 12th registered.
2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →2 of the 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand are open now. Recruiting first, the newest first:
Phramongkutklao College of Medicine and Hospital · Sites in Thailand
Ages 20+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 338 across the 13 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 9 most frequent:
Department of Medical Services Ministry of Public Health of Thailand is the lead sponsor of 39 studies on the registry; 10 are open to participants now.
Department of Medical Services Ministry of Public Health of Thailand has 1 study filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to
Primary Objectives:
Secondary Objectives:
All patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.
This study aims to analyze the impact of the timing of granulocyte colony-stimulating factor (G-CSF) administration on the prevention of febrile neutropenia (FN) in non-Hodgkin's lymphoma patients undergoing standard chemotherapy. G-CSF is a growth factor that stimulates the production of white blood cell in order to fighting infection. When non-Hodgkin's lymphoma patients receive chemotherapy for eradicating cancer cells. They also have collateral damage those white blood cells and other hematopoietic cell lines.
All patients received standard chemotherapy regimens once every four weeks. The study will compare the efficacy of early G-CSF administration, or late administration, after each course of chemotherapy.
The primary endpoint is the incidence of FN in each chemotherapy course. At the end of each chemotherapy course, patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours). All patients will be followed up to monitor for FN events.
Secondary endpoints include the incidence of myelosuppression and quality of life, assessed during outpatient and emergency department visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Early receiving G-CSF group Patients in early receiving G-CSF group accept within 72 hours post chemotherapy
Drug: Early receiving G-CSF group
Last receiving G-CSF group Patients in early receiving G-CSF group accept after 72 hours post chemotherapy
Drug: Late receiving G-CSF group
Early receiving G-CSF group will be given within 72 hours post chemotherapy
Late receiving G-CSF group will be given after 72 hours post chemotherapy
Incidence of febrile neutropenia
Incidence of febrile neutropenia in each course
Time frame: One year
Incidence of leukopenia and neutropenia
Incidence of leukopenia and neutropenia in each course
Time frame: One year
Incidence of grade 3 or 4 of myelosuppression
Incidence of 3 or 4 myelosuppression in each course
Time frame: One year
Time of visits to outpatient (OPD) and emergency clinics (ER)
Incidence of visit to OPD or ER in each course
Time frame: One year
Quality of life (QoL) after chemotherapy
Quality of life score daily in each course
Time frame: One year
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for Feb 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Department of Medical Services Ministry of Public Health of Thailand